Celcuity receives FDA approval for Revtorpyk breast cancer therapy

Celcuity, a small public biotech, announced that the U.S. Food and Drug Administration has cleared its drug Revtorpyk for use in breast cancer patients when combined with fulvestrant.

The approval positions Revtorpyk as a potential alternative to existing treatments from larger companies, aiming to improve outcomes for patients who receive similar therapies from Novartis and Roche.

The decision was reported on July 14, 2026, and marks a significant milestone for Celcuity as it moves from development to market entry.